Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 September 2021 | Story Reuben Maeko | Photo Supplied
Shezree Tiel winner of the student category.

As part of the Faculty of Health Sciences’ Awareness Initiative for Mental Health (FoHS AIM High) to raise awareness regarding mental health and well-being among students and staff, the faculty held a photo competition for its students and staff members. 

The competition with the theme, Things my Gogo taught me, received 70 entries and according to the Programme Director in the School of Clinical medicine, Dr Lynette Van der Merwe, the project was aimed at encouraging students and staff members to show creativity and passion by sharing photos with a reflection on the theme.
For the year 2021, the mental health awareness competition had six (6) winners for both student and staff. The photo competition was judged by Prof Willem Kruger, head of the Department of Community Health and an award-winning photographer.

An opportunity to celebrate grandmothers

Mrs Mary-Ann Naudé, author, and Mrs Madeleen Eygelaar, photographer, were the joint winners of the first prize in the staff category. The competition gave Naude, an Assistant Officer at the Clinical Skills Unit for the School of Health and Rehabilitation Sciences, an opportunity to celebrate the life of her grandmother Mary, whose value, despite her generous soul, was unfortunately not always valued while she was alive.

“The competition made me think of the influences on my life of strong women like my two oumas and my mother. I realised that I am who I am today because of their hard work and their examples. I am overwhelmed with gratitude. I feel honoured that our entry was chosen above the many, many excellent other entries,” says Naudé.

The joint winner of the staff category, Eygelaar, a physiotherapy junior lecturer at the Department of Physiotherapy, says she grew up without a mother, losing hers at a young age, and learnt about life, nature, love and art from her grandmother. 

“I wished to celebrate her, capturing the influence she had over my life. She is still the light in my life and the warmth in my soul, as I am fortunate that she is still alive. However, she lives far away. I was happy to join with Mary-Ann in sharing our love of our grandmothers in order to symbolically capture those expressions of love. 

Mary-Ann Naudé, author, and Madeleen Eygelaar, photographer, were the
joint winners of the first prize in the staff category of the Faculty of Health Sciences’
photo competition with the theme, Things my Gogo taught me.

“The photo competition made me realise what a privilege it is to have a grandmother in your life, who share love and wisdom with you in a gentle and kind manner. Winning the competition, I was surprised, as I did not expect others to feel the same emotions I felt when taking the photos. It is a blessing to touch others with a picture that means so much to me personally. In that regard, I am very thankful. I was impressed with so many other beautiful photos that told the story of the love of their grandmothers, so I was humbled to receive acknowledgement for mine.”


Competition was a way of expressing her journey

The student category winner, Shezree Tiel, who is a third-year medical student, said the competition was a way of expressing her journey in the medical field. She saw an opportunity to tell her story on how she dealt with mental health problems during her studies through a photo. 

Shezree had lost hope in her studies and her mental health was a serious challenge. She wanted to share her story by encouraging other students not to lose hope and the competition gave her motivation to speak out about how she feels and deals with mental-health related issues. 

Given the hardships during COVID-19, Shezree felt happy and courageous to win the prize. “It will help me to encourage others to share how they feel about mental health and well-being,” she said.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept